AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05433948 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Simultaneous EEG and CRT
Description: EEG is recorded with 32 electrodes and commercial recording equipment.10 min EEG is recorded in idle mode with eyes closed prior to continuous EEG recording during the CRT examination, see below.~The test is performed via a laptop using EKHO software. The software generates 150 sound stimuli of 90 dB, which the patient hears in sound-insulated headphones. Via a push button in the dominant hand, the patient must respond as quickly as possible as soon as sounds are perceived.~PSE test: Duration 20 min. Includes 5 tasks: Digit-symbol Test, Number Connecting Test A, Number Connecting Test B, Serial Dotting Test and Line Tracing Test. Exits in 4 versions, which are used in repeated tests to avoid the learning effect. Scores range from -18 t0 6 and less -4 is abnormal.
Study NCT00748540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrant Soundbridge
Description: Mixed and conductive hearing loss using round window stimulation
Study NCT01373567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TINEFCON
Description: Two 700 mg tablets of Tinefcon in the morning and evening to be taken orally.
Study NCT03264313 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Transcranial Magnetic Stimulation
Description: Patients undergoing of Deep Transcranial Magnetic Mtimulation (dTMS) for smoking cessation
Study NCT01958736 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ballistic Strength Training
Description: The experimental group will complete jump squats on the leg sled, single leg toe push offs (or bilateral where unable to complete single), alternating legs (i.e. bounding), mini tramp jumping, progressing to jogging, quick hip flexion and bounding on land.
Study NCT01958736 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Physiotherapy
Description: This group will complete a suite of exercises based upon existing rehabilitation practices that aim to improve mobility after stroke. The supervising physiotherapist will select and progress the exercises, recording the performance of exercises in an exercise log and detailing incidence of adverse events. Exercise selection will include: gait retraining, cardiovascular fitness, lower limb strengthening, static and dynamic balance.
Study NCT01356602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab pre-filled syringe
Description: Canakinumab pre-filled syringe
Study NCT01356602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canakinumab lyophilized powder
Description: Canakinumab lyophilized powder
Study NCT01356602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Triamcinolone Acetonide
Study NCT04332380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma
Description: Day 1: CP-COVID19, 250 milliliters. Day 2: CP-COVID19, 250 milliliters.
Study NCT02761434 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic Saline (3% NaCl)
Description: 0.1 ml of 3% NaCl per kg of body weight per minute
Study NCT02761434 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Saline (0.9% NaCl)
Description: 0.1 ml of 0.9% NaCl per kg of body weight per minute
Study NCT02675712 — intervention group
Intervention type: OTHER
Intervention: African drumming
Description: Rhythmic beating or tapping of a variety of percussion instruments, which often occurs within a group setting
Study NCT01356602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo to Canakinumab (PFS), Canakinumab (LYO) and Triamcinolone Acetonide
Study NCT01356602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to Canakinumab (PFS), Canakinumab (LYO) and Triamcinolone Acetonide
Study NCT02945449 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wharton Jelly Mesenchymal stem cells
Description: Intracavernous injection of Wharton Jelly Mesenchymal stem cells.
Study NCT02720237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: In-person individual sessions (occurring one month apart) and booster phone sessions (occurring 2-3 weeks after each in-person session), delivered by a trained counselor.
Study NCT02720237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET) Intervention
Description: In-person individual sessions (one session per week) and optional group sessions, delivered by a trained counselor.
Study NCT03640858 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theranova Dialyzer
Description: The Theranova dialyzer will be used for each of the hemodialysis treatments beginning week 3 and ending at the end of the dialysis week on week 14 and again starting week 23 and ending at the end of the dialysis week on week 46 . This will allow us to compare patient reported symptoms in weeks 1 and 2 when patients are on their usual dialyzer with their symptoms using the Theranova dialyzer. This will also allow us to see if there is a carry-over effect.
Study NCT02394574 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clean Cookstove
Description: Ethanol
Study NCT02394574 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Cookstove
Description: Firewood / Kerosene
Study NCT03638089 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fall-recovery training
Description: Participants practice recovering from simulated, treadmill-induced slips and trips.
Study NCT02090114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate
Description: DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate and will be administered at 400mg IM every 28 days.
Study NCT04378790 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patching
Description: Procedure in which the eye is covered utilizing a patch to increase the strength of the uncovered eye.
Study NCT04378790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patching
Description: Procedure in which the eye is covered utilizing a patch to increase the strength of the uncovered eye.
Study NCT04378790 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glasses
Description: Eye Glasses are created and worn by patient to improve vision
Study NCT04378790 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glasses
Description: Eye Glasses are created and worn by patient to improve vision
Study NCT00846482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered once every 2 or 3 weeks
Study NCT01469156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab 0.5 or 2.0 mg/0.05 cc
Description: ranibizumab (3:1 ratio of 2mg:0.5 mg ranibizumab) administered in three initial monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and 12 month off drug safety follow up.
Study NCT01469156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab 0.5 or 2.0 mg/0.05 cc
Description: ranibizumab (3:1 ratio of 2mg:0.5 mg ranibizumab) administered in three initial monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and 12 month off drug safety follow up.
Study NCT01813227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.
Study NCT01813227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: If you decide to participate in the study, in addition to the carfilzomib and possible dexamethasone administration, If less than a partial remission (PR) after 4 cycles is achieved, rituximab 375 mg/m2 on day 16 of each subsequent cycle will be added to the treatment. Subjects who meet the criteria for progression prior to 4 cycles of therapy will have rituximab 375 mg/m2 weekly for 4 consecutive weeks every 3 cycles added to the treatment. Subjects will be treated to maximal response plus 2 additional cycles to a maximum of 12 cycles.~At the beginning of every cycle, your study doctor will see if your general health is satisfactory. You will be asked to report any side effects or problems you have had since the start of the last treatment cycle as well as any medication change(s).
Study NCT01813227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.~You will also receive dexamethasone weekly on Days 1, 2, 8, 9, 15 and 16 starting with cycle 1 and continuing every cycle thereafter.
Study NCT02858778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early order of palliative care consultation
Study NCT02090114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Enanthate
Description: Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative. Will be administered at 400mg IM every 28 days.
Study NCT02720237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) Intervention
Description: In-person individual sessions (one session per week) and optional group sessions, delivered by a trained counselor.
Study NCT04196751 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Supervision
Description: After baseline data collection, participants will be invited to attend training on clinical supervision (CS). Education will be delivered in 3 phases. 1-Orientation to the CS model 2-Integration of theory into practice and 3-Skill advancement for supervisors. After training, participants will be encouraged to choose a supervisor, identify objectives for skill development. They will be advised to meet their supervisor once a month for 60 minutes (Due to COVID 19 pandemic the participants can have either one-to-one session in-person or virtually (Microsoft Team), however, if the supervisor and the supervisee working in the same campus can have their one-to-one session as per their preferences. Supervisor-supervisee will be working together to achieve the stated goals. Only the recorded attendance and nature of the session will be used for research purpose. Data will be collected at baseline, 6\&12 month with pre-specified tools.
Study NCT03804255 — intervention group
Intervention type: OTHER
Intervention: Survey Administration
Description: Complete surveys
Study NCT04672616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Description: The intervention is a group psychotherapeutic offer for mentally burdened adolescents and young adults to support their professional integration.
Study NCT00629174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Endurance and resistence training, 90 minutes, 3 times weekly
Study NCT00629174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental activity
Description: Participation at computer lessons, 3 times weekly, 90 minutes each
Study NCT02866994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Connect Online
Description: Three-hour workshop to complete personal website regarding breast cancer experience to share with friends and family
Study NCT02866994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCO PLUS
Description: Three-hour workshop to complete personal website regarding breast cancer experience to share with friends and family, as well as other women diagnosed with breast cancer
Study NCT05019794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: Infigratinib (BGJ398) 125 mg orally daily, 3 weeks on, 1 week off.
Study NCT02887794 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical and psychoacoustic measures
Description: Our study focuses on psychoacoustic tests, specialist care protocols (psychotherapy, neuromodulation ...) being made independently of our study, as part of medical activity of Cerletti care unit or differentiated protocols. Thus, our study shows no individual benefit for the patient. However, a better understanding of the neurophysiological mechanisms underlying auditory hallucinatory phenomenon could allow a better management of these patients in the near future
Study NCT02821650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEJ (Traditional stove to Efficient stove in Jhuggi)
Description: TEJ (means 'Bright' in Hindi) is an improved cook stove, locally designed and manufactured, aimed at reducing the indoor air emissions and improving health outcomes. 'Jhuggi' is a Hindi word which stands for a 'slum dwelling'
Study NCT02214628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fovista® (anti-PDGF BB) plus anti-VEGF
Study NCT00563316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: The first infusion of panitumumab will occur on Cycle 1 Day 4. On Cycle 2 Day 1, panitumumab will be administered on the same day as irinotecan and every 2 weeks thereafter.
Study NCT00563316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: The first infusion of irinotecan will occur on Cycle 1 Day 1. Irinotecan will be administered on the same day as panitumumab on Cycle 2 Day 1 and every 2 weeks thereafter.
Study NCT04910165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Exparel used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine
Study NCT00828945 — intervention group
Intervention type: DEVICE
Intervention: Lipid Self Test
Description: Self test for lipid levels, twice during study period
Study NCT03022890 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hatha yoga
Description: 12 weeks of hour-long gentle hatha yoga classes
Study NCT03022890 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: health education
Description: 12 weeks of hour-long classes on nutrition, sleep, coping with pain, and other health educaiton topics
Study NCT01745887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EBI-005-2
Description: The investigational drug EBI-005-2, is an intervention to three different study arms. One arm gets 5mg/ml, the other gets 20mg/ml and the last arm is Placebo.
Study NCT00574769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001, Docetaxel, Bevacizumab
Description: RAD001 oral, 2.5 mg daily RAD001 oral, 5mg daily~Bevacizumab infusion (IV), 15 mg/kg every 21 days~Docetaxel infusion (IV), 75 mg/m\^2 every 21 days
Study NCT03744286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Slip Training
Description: -On a separate day (visit 2), using the identified optimal distance, a training session that involves 24 passes on the device where 1-2 planks move will be performed.
Study NCT02539368 — intervention group
Intervention type: DRUG
Intervention: CT-P13
Description: biosimilar infliximab
Study NCT02539368 — intervention group
Intervention type: DRUG
Intervention: Remicade
Description: infliximab
Study NCT01570231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bilateral limb ischemic preconditioning (Doctormate, IPC-906X)
Description: Device: bilateral limb ischemic preconditioning (Doctormate, IPC-906X, produced by Beijing Renqiao Institute of Neuroscience)five cycles of 5 minutes bilateral upper limb ischemia-reperfusion performed by inflating tourniquets to 200 mmHg, twice daily for 180 consecutive days, along with conventional medical treatment.
Study NCT05126498 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention was applied
Study NCT04910165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Ropivacaine used in Adductor Canal Block plus Infiltration Between Popliteal Artery and Capsule of Knee using Ropivacaine
Study NCT01269437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide dry powder inhaler
Description: 200mcg per inhalation, twice daily, for 12 weeks
Study NCT01269437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide dry powder inhaler
Description: 200mcg per inhalation, twice daily, for 12 weeks
Study NCT01821014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Patients undergo a detailed history and examination to the degree that is possible using the videoconference program, skype, a digital camera for high-resolution images, and an electronic stethoscope. A clinic volunteer aids with examination, translation and documentation.
Study NCT01821014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-person physician interaction
Description: Patients undergo a detailed history and examination by an in-person physician. A clinic volunteer aids with examination, translation and documentation, as needed.
Study NCT00273910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gp100:209-217 (210M)
Study NCT01821014 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-person physician interaction
Description: Patients undergo a detailed history and examination by an in-person physician. A clinic volunteer aids with examination, translation and documentation, as needed.
Study NCT00087035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Administered as an IV infusion of 60m/m2 over a 1-hour period, once every 21 ± 2 days
Study NCT00087035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Will be taken at a starting daily dose of 150mg
Study NCT03898973 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Quadrivalent inactivated influenza vaccine (IIV)
Description: Intramuscular Injection. Participants will receive the inactivated flu vaccine into anterior quadriceps.
Study NCT01415687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene Glycol-Based Lavage
Description: Split dose Polyethylene Glycol-Based Lavage (2L + 2L)~If arrival for colonoscopy is prior to 10AM: at 12 noon on the day before your colonoscopy drink 2L of PEG within two hours. At 8PM that day, drink the remaining 2L of PEG within two hours.~If arrival for colonoscopy is at or after 10AM: at 8PM on the day before your colonoscopy, drink 2L of PEG within two hours. Starting five hours before your arrival time at the Centre on the day of your colonoscopy, drink the remaining 2L of PEG within two hours.
Study NCT01415687 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pico-Salax (Magnesium Citrate) plus Bisacodyl
Description: If arrival for colonoscopy is prior to 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 12 noon, drink the first packet of Pico-Salax in 8oz water, and the second packet of Pico-Salax in 8oz of water at 8PM. Day of colonoscopy, drink clear fluids.~If arrival for colonoscopy is at or after 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 8PM, drink the first packet of Pico-Salax in 8oz water. Day of colonoscopy, drink the second packet of Pico-Salax in 8oz water five hours before you are to arrive at the Centre.
Study NCT02913326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Study NCT02913326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Study NCT00474357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Structured Psychoeducation Group Therapy
Description: weekly brief structured psychoeducation group therapy for seven weeks for bipolar patients
Study NCT04126174 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: femtosecond laser system arcuate corneal incision
Description: Corneal arcuate incision made either with a blade (manual) or femtosecond laser system.
Study NCT00273910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA-51
Study NCT00273910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Apply imiquimod 5% cream to the skin at the site of injection daily for 5 days
Study NCT00910988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: olanzapine/Zyprexa
Study NCT00910988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine
Description: olanzapine/Zyprexa
Study NCT00910988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ziprasidone
Description: ziprasidone/Geodon
Study NCT00910988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: ziprasidone/Geodon
Study NCT01428362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-1121